Overview
Lobbying Costs
557,000€
Financial year: Jan 2016 - Dec 2016
Lobbyists (Full time equivalent)
2.25 Fte (6)
Lobbyists with EP accreditation
4
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Shire (Shire)
EU Transparency Register
60329985751-43 First registered on 28 Apr 2011
Goals / Remit
Shire is the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening.
We are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.Main EU files targeted
All initiatives, policies, and legislation related to the biopharmaceutical sector and patient access to innovative medicines. These include:
European Commission's annual work programme
European Medicines Agency
Healthcare policies
Health Technology Assessment
Innovative Medicines Initiative
Intellectual Property
Patient access to innovative medicines
Patient safety
Personalised medicines
Pharmaceutical legislation
Pharmaceutical sector policies
Rare disease policies
Research & DevelopmentAddress
Head Office
Riverwalk; Citywest Business Campus, 5
Dublin 24
IRELANDEU Office
47, rue Montoyer
Brussels 1000
BELGIUM -
People
Total lobbyists declared
6
Employment time Lobbyists 50% 3 25% 3 Lobbyists (Full time equivalent)
2.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
4 accreditations were / are live (in bold) for the selected state of 21 Apr 2017
Name Start date End Date Mr Richard CORLISS 12 Oct 2017 12 Oct 2018 Mr Toon DIGNEFFE 12 Oct 2017 12 Oct 2018 Mr Richard CORLISS 30 Sep 2016 23 Sep 2017 Ms Maria Joaquina RODRIGUEZ SANCHEZ 30 Sep 2016 22 Sep 2017 Ms Astrid Jankowitsch 30 Sep 2016 27 Sep 2017 Mr Toon DIGNEFFE 30 Sep 2016 24 Sep 2017 Mr Maciej Gajewski 11 Sep 2015 09 Sep 2016 Mr Richard CORLISS 11 Sep 2015 09 Sep 2016 Mr Nicholas Edwards 16 May 2014 05 Jun 2015 Mr Emmanuel Chantelot 15 May 2014 05 Jun 2015 Mr Maciej Gajewski 13 May 2014 05 Jun 2015 Complementary Information
None declared
Person in charge of EU relations
Mr Toon Digneffe (Head, EU Public Affairs)
Person with legal responsibility
Mr Flemming Ornskov (Chief Executive Officer)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Shire is a member of:
European Association of Bioindustries (EuropaBio)
European Biopharmaceutical Enterprises (EBE)
European Biosimilars Group (EBG)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Plasma Protein Therapeutics Association (PPTA)
American Chamber of Commerce to the European Union (AmCham EU)
British Chamber of Commerce in Belgium
European Policy Centre (EPC)
Friends of EuropeMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2016 - Dec 2016
Lobbying costs for closed financial year
557,000€
Other financial info
Activities covered: staff cost, trade associations membership fees, fees for public affairs consultancies and administrative expenses.
This estimate is consistent with the guidance provided by EFPIA.
Note that on 3 June 2016 Shire completed its combination with Baxalta Incorporated. Shire’s registration in the EU Transparency Register has been updated to reflect this. Shire will provide further information including 2017 financial data in its next annual update. -
EU Structures
Groups (European Commission)
None
ACC
None
Groups (European Parliament)
None
Communication activities
The revision of the Orphan Medicinal Products implementing guidelines.
Follow-up actions related to the 2009 Council Recommendation on an action in the field of rare diseases.
European Commission review of the Paediatric Regulation.
Setting-up of the European Commission initiative on rare cancers.
Implementation of the Clinical Trials Regulation (536/2014).
Debates and initiatives on international reference pricing of medicines.
European cooperation mechanisms on Health Technology Assessment e.g. EUnetHTA.Other activities
Shire engages in debates on issues relevant to the biopharmaceutical sector. Shire supports equal access to innovative medicines in Europe and research and innovation in the healthcare sector.
Shire also interacts with the EU Institutions in relation to legislation which has impact on the industry, for example Shire participates in relevant public consultations.- Meetings
Meetings
None declared
- Meetings